ERYTECH Announces a Poster Presentation for TRYbeCA1 at the ASCO 2020
Greater than 50% enrollment achieved in ongoing Phase 3 trial of eryaspase in pancreatic cancer
Trial in Progress Poster selected for inclusion in Poster Walk
Lesen Sie auch
LYON, France and CAMBRIDGE, Mass., Jan. 24, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing
innovative therapies by encapsulating drug substances inside red blood cells, today announced the presentation of a Trial in Progress Poster for the ongoing Phase 3 TRYbeCA1 trial evaluating
eryaspase in second-line pancreatic cancer at the American Society of Clinical Oncology (ASCO) 2020 Gastrointestinal Cancers Symposium in San Francisco.
TRYbeCA1 is planned to enroll approximately 500 patients in approximately 100 clinical sites in Europe and the U.S. In this trial, eligible patients are randomized 1-to-1 to receive eryaspase
in combination with standard chemotherapy (gemcitabine/nab paclitaxel or an irinotecan based regimen) or chemotherapy alone. To date, more than 50% of the patients for TRYbeCA1 have been
enrolled. The primary endpoint of TRYbeCA1 is overall survival with an interim efficacy analysis planned for when approximately two-thirds of events have occurred.